“…For example, the interconnection of quantitative models of the human physiology (e.g., Physiomodel, Mateják and Kofránek, 2015), drugs pharmacokinetics/pharmacodynamics (e.g., Open Systems Pharmacology Suite, Eissing et al, 2011), (possibly semi-autonomous) biomedical devices, pharmacological protocol guidelines or treatment schemes, enables the set-up of in silico clinical trials for the (model-based) safety and efficacy pre-clinical assessment of such drugs, protocols, treatments, devices, using standard system engineering approaches to perform their simulation-based analysis at system level (see, e.g., Kanade et al, 2009;Mancini et al, 2013Mancini et al, , 2014Zuliani et al, 2013;Zuliani, 2015;Mancini et al, 2016aMancini et al, , 2017. Works in this direction include, e.g., (Schaller et al, 2016;Messori et al, 2018), where a model-based verification activity of a sensor-augmented insulin pump is conducted against a model of the human glucose metabolism in patients with diabetes mellitus, (Madec et al, 2019), where a model of a penicillin bio-sensor (integrating biochemistry, electrochemistry, and electronics models) is simulated to compute a first dimensioning of the sensor, and (Tronci et al, 2014;Mancini et al, 2015), where representative populations of virtual patients are generated from parametric models of the human physiology, a key step to enable in silico clinical trials (see, e.g., Mancini et al, 2018).…”